Please use this identifier to cite or link to this item:
Title: Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy
Author: Vélez, Rita
Gállego Culleré, M. (Montserrat)
Keywords: Leishmaniosi
Issue Date: 8-Feb-2020
Publisher: John Wiley & Sons
Abstract: Canine leishmaniosis is an important vector-borne zoonosis caused mainly by Leishmania infantum. Diagnosis and treatment of affected individuals can be particularly complex, hindering infection control in endemic areas. Methods to prevent canine leishmaniosis include the use of topical insecticides, prophylactic immunotherapy and vaccination. Four vaccines against canine leishmaniosis have been licensed since 2004, two in Brazil (Leishmune®, the production and marketing license of which was withdrawn in 2014, and Leish-Tec®) and two in Europe (CaniLeish® and LetiFend®). After several years of marketing, doubts remain regarding vaccine efficacy and effectiveness, potential infectiousness of vaccinated and infected animals or the interference of vaccine-induced antibodies in L. infantum serological diagnosis. This review summarizes the scientific evidence for each of the vaccines commercially approved for canine leishmaniosis, while discussing possible weaknesses of these studies. Furthermore, it raises the need to address important questions related to vaccination impact in Leishmania-endemic countries and the importance of post-marketing pharmacological surveillance.
Note: Versió postprint del document publicat a:
It is part of: Tropical Medicine & International Health, 2020, vol. 25, num. 5, p. 540-557
Related resource:
ISSN: 1360-2276
Appears in Collections:Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Biologia, Sanitat i Medi Ambient)

Files in This Item:
File Description SizeFormat 
695761.pdf884.46 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.